How to Read a Peptide Certificate of Analysis: HPLC, Mass Spectrometry, Purity and Lot Numbers

A peptide certificate of analysis, usually shortened to COA, is a summary of the analytical results reported for a specific sample or production lot. A useful COA should help a research buyer answer four separate questions:

1. Which material and batch were tested?
2. Was the reported molecular identity supported by an appropriate analytical method?
3. What did the stated purity or content test measure?
4. What important quality attributes were not tested?

Those questions must be considered separately. A large purity percentage does not, by itself, establish molecular identity, net quantity, sterility, endotoxin status or suitability for a particular experiment. The value of a COA comes from the connection between the sample, the method, the reported result and the underlying evidence.

This guide explains how to read those parts without treating one number as proof of everything.

Start with traceability, not the purity percentage

Before reviewing the chromatogram, confirm that the document can be connected to the material in front of you. The identifying information normally appears near the top of the COA or in a sample-summary table.

Check the following fields:

• Product or sample name: The name should match the vial label and the item ordered. Watch for similar names, blends and salt forms.
• Lot or batch number: This should match the lot printed on the vial, carton or supplied batch record. A COA from a different lot is not batch-specific evidence for the material received.
• Report number: A unique report identifier helps distinguish the document from reused templates or previous analyses.
• Sample receipt and analysis dates: These establish when the laboratory received and tested the sample. They do not automatically establish a shelf life.
• Manufacturer or client: These fields show who supplied or commissioned the sample. They should not be confused with the identity of the testing laboratory.
• Laboratory identity: A reader should be able to identify the organization that generated the report and, where relevant, verify the report through the laboratory or supplier’s batch-record system.

If the product name or lot number does not match, stop there. A technically detailed chromatogram cannot repair a broken chain between the report and the vial.

Understand what “identity” means

Identity testing asks whether the analytical evidence is consistent with the material claimed on the label. For synthetic peptides, mass spectrometry is commonly used as part of that assessment because it can compare an observed molecular mass or mass-to-charge pattern with an expected value.

The result may appear as:

• an observed molecular mass;
• an expected or theoretical molecular mass;
• one or more mass-to-charge peaks;
• a pass/fail identity statement; or
• a spectrum attached to the report.

The exact presentation depends on the instrument and method. Peptides can produce several charged ions, adducts or related signals, so a spectrum should be interpreted under the laboratory’s method rather than by selecting the largest number on the page.

Mass-based agreement is valuable evidence, but it has limits. It does not automatically demonstrate purity, content, sterility, biological activity or every aspect of molecular structure. Regulatory analytical guidance similarly treats identification, assay, purity and impurity testing as distinct analytical purposes. The FDA’s Q6A guidance also notes that identification based only on a single chromatographic retention time is not considered sufficiently specific and describes combinations such as HPLC/MS as stronger identification approaches.

Read the HPLC purity result in context

High-performance liquid chromatography, or HPLC, separates detectable components under a defined set of experimental conditions. A chromatogram displays detector response against retention time. Each visible peak represents a detected response at a particular point in the run.

Peptide COAs frequently report an area percentage, such as 99.5%. In simplified terms, that value is commonly derived from the target peak’s integrated area relative to the total integrated peak area included by the method.

That does not mean that 99.5% of everything in the vial has been exhaustively identified. The reported percentage depends on factors such as:

• the chromatographic column and mobile phase;
• gradient and run time;
• detection wavelength or detector type;
• sample preparation and injected concentration;
• integration rules and reporting threshold;
• whether an impurity is separated from, or co-elutes with, the main peak; and
• which substances produce a response under the selected conditions.

This is why the method matters. ICH Q2(R2) treats specificity/selectivity, range, accuracy and precision as distinct parts of analytical procedure validation. Research on pharmaceutical peptide chromatography also shows that closely related impurities can be difficult to resolve and that orthogonal or multidimensional methods may be needed when compounds co-elute.

When reading a peptide HPLC section, look for:

• a clearly stated purity result;
• a chromatogram that corresponds to the reported sample;
• labelled axes and retention time;
• the method or enough method context to understand the result;
• a plausible main peak and disclosed secondary peaks; and
• consistency between the summary table and chromatogram.

A clean-looking image alone is not a result. The reported value should be connected to a defined analytical procedure and the correct batch.

Do not confuse purity with net content

Purity and net content answer different questions.

• Purity describes the relative result produced by the stated purity method.
• Net content or peptide content addresses how much reported material is present in the container or sample.

A vial may have a high chromatographic purity result while its measured content differs from the labelled quantity. Conversely, a content result close to the label claim does not establish that all detected material is the intended peptide.

If a COA reports net content, check:

• the unit, normally mg or another mass unit;
• whether the value refers to the peptide, total dry material or another defined basis;
• the test method;
• whether the result is for one vial, a composite sample or a batch average; and
• whether an uncertainty or acceptance range is provided.

Do not convert a net-content number directly into a solution concentration without also knowing the validated preparation volume and method. Mass, volume and concentration are related, but they are not interchangeable.

Check blends component by component

For a multi-component blend, a single overall percentage may not answer whether every listed component was identified and quantified appropriately.

A more useful blend report should make clear:

• which components were tested;
• whether identity was assessed for each component;
• the reported content of each component;
• how overlapping chromatographic or mass-spectral signals were handled; and
• whether the stated total refers to combined content or a separate measurement.

The sample name on the report should also match the blend name and strength on the product label. A COA for one ingredient is not evidence for the full composition of a three-component blend.

Know what the COA does not establish

Only attributes explicitly tested and reported should be treated as results. HPLC purity and mass-spectrometry identity do not automatically demonstrate:

• sterility;
• bacterial endotoxin level;
• bioburden;
• residual solvent content;
• water content;
• counterion content;
• pH after preparation;
• stability or expiration period;
• biological potency; or
• safety or effectiveness in humans or animals.

Some projects require additional tests, specifications or handling records. The appropriate set depends on the material, intended laboratory use and applicable quality system. A COA should not be expanded beyond what its listed methods actually support.

Use this practical COA review checklist

Before accepting a peptide COA as relevant evidence, confirm each item below.

Check	What to confirm	Warning sign
Product	Name and form match the order and label	Similar but different compound or blend
Lot	COA lot matches the physical vial or carton	Missing or different lot number
Report	Unique report number and identifiable laboratory	Generic document with no traceable report ID
Dates	Receipt and analysis dates are shown	Dates missing or inconsistent
Identity	Identity method and result are stated	Identity inferred only from product name
Purity	Method-specific result is linked to a chromatogram	Percentage displayed without supporting context
Content	Quantity, unit and measurement basis are clear	Purity percentage presented as vial content
Scope	Untested attributes are not implied	HPLC/MS claimed to prove sterility or safety
Verification	Report can be matched to a supplier or laboratory record	Reused image with no batch connection

How Newt batch verification fits into the review

Newt’s COA verification page is designed to connect a product or report record with its batch documentation. When reviewing a Newt product, use the lot or report information supplied with the product and compare it with the corresponding record in the COA library.

The verification step confirms document-to-batch correspondence; this article explains how to interpret the fields after the correct record has been found. These are related but different tasks.

• Use Verify COA to locate the relevant Newt batch record.
• Use this guide to interpret the report number, identity result, net content, purity result and chromatogram.
• Contact Newt if the product label and published batch information do not agree.

The key principle

The strongest COA is not necessarily the one with the largest number in bold type. It is the one that clearly connects the correct batch to appropriate analytical procedures, reports the results without overstating their meaning and makes the limits of the testing visible.

Read the document in this order:

1. Verify the product, lot and report identifiers.
2. Review identity evidence.
3. Review HPLC purity under the stated method.
4. Review net content separately.
5. Check the scope for tests that were not performed.
6. Confirm the document against the supplier or laboratory record.

That sequence provides a more reliable review than treating a purity percentage as a universal quality score.

References

1. U.S. Food and Drug Administration. Analytical Procedures and Methods Validation for Drugs and Biologics.
2. International Council for Harmonisation. ICH Q2(R2): Validation of Analytical Procedures.
3. U.S. Food and Drug Administration. Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products.
4. Nailor A, et al. Reference Standards to Support Quality of Synthetic Peptide Therapeutics. Pharmaceutical Research. 2023;40(6):1317–1328.
5. Stoll DR, et al. A strategy for assessing peak purity of pharmaceutical peptides using two-dimensional liquid chromatography coupled to mass spectrometry. Journal of Chromatography A. 2023.

---

Research-use notice: This article is provided for educational and laboratory reference only. It does not establish product suitability for a particular experiment and is not medical advice, a clinical protocol or a recommendation for human or veterinary use.

Continue your review

Connect the guide to a batch record.

Use Newt’s COA library to locate available batch documentation, or browse the current research catalog.

Verify COA →Browse products →